Retinitis Pigmentosa Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.A Study in Subjects With Retinitis Pigmentosa
Condition: Retinitis Pigmentosa Intervention: Drug: ADX-2191 Sponsor: Aldeyra Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2022 Category: Research Source Type: clinical trials
Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa; Retinitis Pigmentosa Syndrome Intervention: Drug: EA-2353 Sponsor: Endogena Therapeutics, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2022 Category: Research Source Type: clinical trials
A Study in Subjects With Retinitis Pigmentosa
Condition: Retinitis Pigmentosa Intervention: Drug: ADX-2191 Sponsor: Aldeyra Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2022 Category: Research Source Type: clinical trials
Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa; Retinitis Pigmentosa Syndrome Intervention: Drug: EA-2353 Sponsor: Endogena Therapeutics, Inc Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2022 Category: Research Source Type: clinical trials
A Study in Subjects With Retinitis Pigmentosa
Condition: Retinitis Pigmentosa Intervention: Drug: ADX-2191 Sponsor: Aldeyra Therapeutics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2022 Category: Research Source Type: clinical trials
